New research examines both the long-term biological aging effects of childhood cancer treatments and proposes alternative treatment sequencing strategies to prevent tumor resistance and improve cure rates.
Klothea Bio has initiated a Phase 1b clinical trial of AKL003, an alpha Klotho mRNA therapeutic designed to extend human lifespan. The randomized, placebo-controlled study is enrolling 21 healthy adults in Prospera, Honduras.
DNA methylation-derived Protein EpiScores significantly improved prognostic accuracy for colorectal cancer survival when added to traditional clinical risk factors, raising concordance indices from 0.64 to 0.70 for disease-free survival and 0.70 to 0.75 for overall survival.
